EGFR and non-small cell lung carcinoma: In a large number of retrospective clinical trials, it has been suggested that NSCLC patients treated with EGFR-TKIs, whose tumors are carrying sensitizing EGFR mutations achieve an improvement of survival [71-78], although this effect has not always been demonstrated [17,79-81].